Experimental 1 H NMR spectra were determined on a Bruker 300 spectrometer using tetramethylsilane as an internal standard. Mass spectral data were obtained using a Finnegan LCQ electrospray mass spectrometer in positive ion mode at atmospheric pressure. Medium-pressure flash column chromatography was done on a CombiFlash Companion system using Teledyne Isco prepacked silica gel columns or using EM Science silica gel 60 Å (230-400 mesh). All reactions were followed by thin-layer chromatography using Whatman silica gel 60 TLC plates and were visualized by UV. Optical rotations were measured on an Auto Pol III polarimeter. All solvents were reagent grade. CMA-80 is a mixture of 80% chloroform, 18% methanol, and 2% concentrated ammonium hydroxide. Purity of compounds (>95%) was established by elemental analysis. Elemental analyses were performed by AtlanticMicrolab, Inc., Atlanta, GA. IUPAC nomenclature is used in the experimental section to name target compounds.
reaction mixture was stirred at 100 °C for 2.5 h, cooled to room temperature, and quenched with H 2 O (10 mL). To the mixture was added Et 2 O (15 mL) and shaken vigorously. The layers were separated, and the aqueous layer was extracted twice with Et 2 O (10 mL). The pooled organic solution was concentrated by rotary evaporation, and the residue was subjected to column chromatography on silica gel eluting with hexane-EtOAc (5:1). The combined fractions containing the product were subjected to rotary evaporation, and the remaining oil was dried under high vacuum.
c. Removal of the N-Boc and O-Me Protecting Groups with BBr 3 . Under an argon atmosphere, 1 eq of Boc-protected phenylpiperazine 8 was dissolved in CH 2 Cl 2 (20 mL), and the solution was cooled to -78 °C. Into this mixture, 4 eq of BBr 3 as a 1 M solution in CH 2 Cl 2 were introduced. The reaction mixture was stirred for 4 h, warmed to 0 °C, and stirred for an additional 2 h. Into this solution dry MeOH (20 mL) was slowly added, and the solution was stirred for 5 min. The solvents were then removed under reduced pressure at 25 °C. The residue was redissolved in MeOH (20 mL), and the solvents were removed again under reduced pressure to afford a residue that was recrystallized or converted to the freebase and purified by column chromatography on silica gel to yield the product.
d. Removal of the N-Boc and O-Me Protecting Groups with Conc. HBr. In a roundbottom flask 8 were dissolved in conc. HBr, and the solution was refluxed for 16 h. Removal of the solvents by rotary evaporation gave a residue that was dissolved in MeOH. This solution was stirred over excess NaHCO 3 for 10 min and then filtered. The solution was concentrated under reduced pressure and subjected to column chromatography on silica gel to afford the product. e. Reductive Alkylation of 9a-e with 3-Phenylpropanaldehyde. In a dry flask 1 eq of phenylpiperazine 9a-e was dissolved in 1,2-dichloroethane (20 mL) along with 1.5 eq of 3phenylpropanaldehyde and 1.5 eq of Et 3 N. The solution was cooled to 0 °C, and 1.5 eq of Na(OAc) 3 BH was then added. The reaction mixture was stirred for 1 h at 0 °C, allowed to warm to 25 °C. After stirring for 2 h, the reaction mixture was added to a concentrated solution of NaHCO 3 (20 mL) and shaken vigorously. The layers were separated, and the organic layer was washed once with H 2 O (5 mL) and once with brine (5 mL). The organic solution was dried (MgSO 4 ), filtered, and the solvents removed under reduced pressure to yield the product which was purified as specified.
(2S,5S)-1-tert-Butoxycarbonyl-2,5-dimethylpiperazine (7e). A solution of 2.80 g (10.14 mmol) of (2S,5S)-2,5-dimethylpiperazine 2 was dissolved in 30 mL of MeOH along with 1.42 mL (10.14 mmol) of Et 3 N. Into this solution was added 1.11 g (5.073 mmol) of Boc 2 O and the solution was stirred overnight. The solution was subjected to rotary evaporation and added 20 mL of CH 2 Cl 2 and 20 ml of conc. NaHCO 3 . The mixture was shaken thoroughly and the layers separated. The organic layer was extracted twice with conc. NaHCO 3 and the organic layer dried over MgSO 4 , filtered and the solvents removed. The residue was purified by silica-gel column chromatography to yield 607 mg (43%) of pure 7e as a clear oil. 1 
(2S)-1-tert-Butoxycarbonyl-4-(3-methoxyphenyl)-3-methylpiperazine (8b).
General procedure a. was employed using 1.32 g (6.60 mmol) of Boc-piperazine 7b 3 to obtain, after chromatography, 1.19 g (59%) of 8b as a yellow oil with spectra identical to that of 8c.
(2R)-1-tert-Butyoxycarbonyl-4-(3-methoxyphenyl)-3-methylpiperazine (8c). General procedure a. was employed using 1.00 g (5.00 mmol) of Boc-piperazine 7c to obtain, after chromatography, 841 mg (55%) of 8c as a yellow oil. 1 (2S,5R)-1-Allyl-4-(3-methoxyphenyl)-2,5-dimethylpiperazine (11). General procedure a. was employed using 1.00 g (6.48 mmol) of allyl-piperazine 10 4 to obtain, after chromatography, 715 mg (55% yield) of 11 as a yellow oil. 1 (cis)-3-(2,6-Dimethylpiperazin-1-yl)phenol (9d). General procedure d. was employed using 407 mg (1.27 mmol) of 8d and 10 mL of conc. HBr. The dihydrobromide salt was dissolved in MeOH, stirred over 200 mg of NaHCO 3 for 10 min, and filtered. The solution was concentrated under reduced pressure and subjected to column chromatography on silica gel eluting with CMA80 to afford 180 mg (65%) of 9d as a brown solid: mp > 220 °C. 1 To this mixture was added 50 mg of 10% Pd on carbon, and the suspension was heated and stirred at reflux for 12 h. The mixture was cooled, filtered, and the solvents evaporated under reduced pressure. To the residue was added 20 mL of conc. NaHCO 3 , and this mixture was extracted thoroughly with EtOAc. The pooled organic extracts were washed once with brine, dried over MgSO 4 , and the solvents removed under reduced pressure to yield 605 mg of an orange oil that was pure 12 by NMR. 1 (2R,5S)-3-(2,5-Dimethylpiperazin-1-yl)phenol (13). General procedure c. was employed using 363 mg (1.65 mmol) of 12 affording a residue that was dissolved in 5 mL of MeOH and stirred over excess NaHCO 3 . The mixture was filtered, and the solvents subjected to rotary evaporation to afford a residue that was purified by chromatography affording 215 mg of 13 as a white solid (63% yield). Spectral information for this compound was found to be identical to 17.
3-(4-Phenylpropylpiperazin-1-yl)phenol (5a) Dihydrochloride. General procedure e. was employed with 250 mg (0.735 mmol) of 9a. The crude product was subjected to flashcolumn chromatography on silica gel eluting with CMA80-CH 2 Cl 2 (1:1). The freebase thus recovered was converted to the dihydrochloride salt by dissolving in 2 mL of a 2 M HCl solution in EtOH and removing the solvents under reduced pressure. The solids were suspended in EtOAc and collected by filtration to yield 55 mg (20 %) of 5a•2HCl as a tan powder: mp 194-201 °C (dec). 1 Conformational Analysis of 5a and 5c. Molecular modeling calculations were performed using Tripos Sybyl version 8.1 running on a dual-processor Apple Mac Pro workstation. Threedimensional models of 5a and 5c were built using the Sybyl fragment library and optimized using the MMFF94 force-field and charges. For 5a model structures of the four possible nitrogen conformers (1-axial, 4-axial; 1-axial, 4-equatorial; 1-equatorial, 4-axial; and 1-equatorial, 4equatorial) were separately generated by nitrogen inversion. For 5c, the eight possible conformers (the four nitrogen substituent conformers × the two methyl conformations for each) were also separately generated. Systematic conformational searches were then performed to establish the local minimum energy conformation of the nitrogen substituents for the set 5a and 5c nitrogen invertomer models. Each of the local minimum energy conformations was then relaxed by a final energy minimization. The energy differences were then calculated from the MMFF94 force-field energies.
Pharmacology. Compounds 5a-h were first evaluated at 10 µM for intrinsic activity in the [ 35 S]GTPγS binding assay at all three opioid receptors. As none of the compounds displayed measurable intrinsic activity at this concentration, they were evaluated for functional antagonism at the opioid receptors. These data were obtained by monitoring the ability of test compounds to inhibit stimulated [ 35 S]GTPγS binding produced by the selective agonists DAMGO (µ), DPDPE (δ), or U69,593 (κ) using cloned human opioid receptors expressed in CHO cells. Agonist dose response curves were run in the presence or absence of a single concentration of test compound. Test compound assay concentrations ranged from 1-5000 nM, depending on their activity. The K e values were calculated using the formula: K e =[L]/DR -1, where [L] is the concentration of test compound and DR is the ratio of agonist EC 50 value in the presence or absence of test compound, respectively. At least two different concentrations of test compound were used to calculate the Ke, and the concentrations were chosen such that the agonist EC 50 exhibited at least a 4-fold shift to the right and there was a clear upper asymptote to the agonist + compound concentration response curve.
